XML 99 R49.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Acquisitions (Details Textual) (USD $) | 0 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 0 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 15, 2012 | May 31, 2012 | May 31, 2013 | May 22, 2012 | May 31, 2014 | May 31, 2014 | Feb. 28, 2014 | Nov. 30, 2013 | Aug. 31, 2013 | May 31, 2013 | Feb. 28, 2013 | Nov. 30, 2012 | Aug. 31, 2012 | May 31, 2012 | Feb. 01, 2013 | Aug. 15, 2013 | Sep. 19, 2013 | Dec. 31, 2013 | Mar. 22, 2012
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  | $ 309,091,000 us-gaap_Goodwill | $ 355,637,000 us-gaap_Goodwill |  | 360,473,000 us-gaap_Goodwill | $ 360,473,000 us-gaap_Goodwill |  |  |  | $ 355,637,000 us-gaap_Goodwill |  |  |  | $ 309,091,000 us-gaap_Goodwill |  |  |  |  |
Projected Angio Vac ten year net sales following closing | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Senior secured term loan facility |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000,000 ango_SecuredLongTermDebtInitialBorrowingCapacity |  |
Purchase consideration placed in escrow |  |  |  |  | 19,100,000 ango_PurchaseConsiderationPlacedInEscrowAmount | 19,100,000 ango_PurchaseConsiderationPlacedInEscrowAmount |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase consideration placed in escrow in cash |  |  |  |  | 14,000,000 ango_PurchaseConsiderationCashAmountPlacedInEscrow | 14,000,000 ango_PurchaseConsiderationCashAmountPlacedInEscrow |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase consideration placed in escrow as common stock |  |  |  |  | 415,000 ango_PurchaseConsiderationNumberOfCommonStockPlacedInEscrow | 415,000 ango_PurchaseConsiderationNumberOfCommonStockPlacedInEscrow |  |  |  |  |  |  |  |  |  |  |  |  |
Cash from escrow fund |  | 2,500,000 ango_ProceedsFromEscrowFund | 2,500,000 ango_ProceedsFromEscrowFund |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biomedical Polymer Additive [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired intangible asset |  |  |  | 12,100,000 us-gaap_IndefinitelivedIntangibleAssetsAcquired / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = ango_BiomedicalPolymerAdditiveMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Power Injectable Port [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired intangible asset |  |  |  | 3,000,000 us-gaap_IndefinitelivedIntangibleAssetsAcquired / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = ango_PowerInjectablePortMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Customer relationships [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  | 10 years 7 months 6 days |  | 11 years 10 months 24 days |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired finite lived intangible assets |  |  |  | 49,400,000 us-gaap_FinitelivedIntangibleAssetsAcquired1 / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_CustomerRelationshipsMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  | 15 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trademarks [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  | 9 years 10 months 24 days |  | 8 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets acquired other than goodwill |  |  |  | 32,500,000 us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_TrademarksMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired finite lived intangible assets |  |  |  | 3,900,000 us-gaap_FinitelivedIntangibleAssetsAcquired1 / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_TrademarksMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  | 7 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
In-process R&D acquired [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired | 15,100,000 us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = ango_ResearchAndDevelopmentMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired intangible asset |  |  |  | 15,100,000 us-gaap_IndefinitelivedIntangibleAssetsAcquired / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = ango_ResearchAndDevelopmentMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Technology [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired finite lived intangible assets |  |  |  | 10,100,000 us-gaap_FinitelivedIntangibleAssetsAcquired1 / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = ango_TechnologyMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  | 6 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  | 20 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Navilyst [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash payments at closing total |  |  |  | 97,000,000 us-gaap_PaymentsToAcquireBusinessesGross / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Liabilities assumed |  |  |  | 18,287,000 us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total estimated purchase consideration |  |  |  | 361,000,000 us-gaap_BusinessCombinationConsiderationTransferred1 / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  |  | 144,705,000 us-gaap_Goodwill / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition of related cost\transaction and related costs |  |  |  |  |  | 1,300,000 us-gaap_BusinessCombinationAcquisitionRelatedCosts / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember | 1,400,000 us-gaap_BusinessCombinationAcquisitionRelatedCosts / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember | 1,600,000 us-gaap_BusinessCombinationAcquisitionRelatedCosts / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember | 1,200,000 us-gaap_BusinessCombinationAcquisitionRelatedCosts / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember | 2,100,000 us-gaap_BusinessCombinationAcquisitionRelatedCosts / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember | 1,300,000 us-gaap_BusinessCombinationAcquisitionRelatedCosts / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember | 1,700,000 us-gaap_BusinessCombinationAcquisitionRelatedCosts / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember | 2,200,000 us-gaap_BusinessCombinationAcquisitionRelatedCosts / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember |  |  |  |  |  |
Issuance of common stock |  |  |  | 9,500,000 us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Senior secured term loan facility |  |  |  | 150,000,000 ango_SecuredLongTermDebtInitialBorrowingCapacity / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Closing price of stock |  |  |  | $ 12.44 us-gaap_BusinessAcquisitionSharePrice / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction and severance costs related to acquisition |  |  | 7,300,000 ango_TransactionAndSeveranceCostsRelatedToAcquisition / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember |  |  |  |  |  |  |  |  |  |  | 11,200,000 ango_TransactionAndSeveranceCostsRelatedToAcquisition / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember |  |  |  |  |
Intangible assets acquired other than goodwill |  |  |  | 107,100,000 us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business acquisition proforma net income loss attributable to different component |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,897,000 us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember |  |  |  |  |
Adjustment related to credit facility due to business acquisition |  | 150,000,000 ango_DebtFinancingForBusinessAcquisitionAmount / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember |  |  |  |  |  |  |  |  |  |  |  | 150,000,000 ango_DebtFinancingForBusinessAcquisitionAmount / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember |  |  |  |  |
Navilyst [Member] | Trademark-NAMIC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired intangible asset |  |  |  | 28,600,000 us-gaap_IndefinitelivedIntangibleAssetsAcquired / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = ango_TrademarkNamicMember | 28,600,000 us-gaap_IndefinitelivedIntangibleAssetsAcquired / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = ango_TrademarkNamicMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Avista Capital Partners [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock |  |  |  |  | 9,400,000 us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued / us-gaap_BusinessAcquisitionAxis = ango_AvistaCapitalPartnersMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, outstanding shares, percentage |  |  |  |  | 27.00%ango_BusinessAcquisitionPercentageOfEquityInterestsIssued / us-gaap_BusinessAcquisitionAxis = ango_AvistaCapitalPartnersMember | 27.00%ango_BusinessAcquisitionPercentageOfEquityInterestsIssued / us-gaap_BusinessAcquisitionAxis = ango_AvistaCapitalPartnersMember |  |  |  |  |  |  |  |  |  |  |  |  |
Vortex Medical [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash payments at closing total | 15,105,000 us-gaap_PaymentsToAcquireBusinessesGross / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Liabilities assumed | 661,000 us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total estimated purchase consideration | 75,292,000 us-gaap_BusinessCombinationConsiderationTransferred1 / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated fair value contingent consideration | 60,302,000 us-gaap_BusinessCombinationContingentConsiderationLiability / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill | 29,519,000 us-gaap_Goodwill / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  | 29,519,000 us-gaap_Goodwill / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember | 29,519,000 us-gaap_Goodwill / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  | 15 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition of related cost\transaction and related costs |  |  | 645,000 us-gaap_BusinessCombinationAcquisitionRelatedCosts / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  | 162,000 us-gaap_BusinessCombinationAcquisitionRelatedCosts / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of annual net sales, first limit |  |  |  |  | 10.00%ango_BusinessAcquisitionContingentConsiderationPayableAsPercentageOfAnnualNetSalesFirstLimit / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember | 10.00%ango_BusinessAcquisitionContingentConsiderationPayableAsPercentageOfAnnualNetSalesFirstLimit / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |
Annual net sales, first limit |  |  |  |  | 150,000,000 ango_BusinessAcquisitionContingentConsiderationPayableBasisAnnualNetSalesFirstLimitMaximum / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember | 150,000,000 ango_BusinessAcquisitionContingentConsiderationPayableBasisAnnualNetSalesFirstLimitMaximum / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of annual net sales, second limit |  |  |  |  | 12.50%ango_BusinessAcquisitionContingentConsiderationPayableAsPercentageOfAnnualNetSalesSecondLimit / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember | 12.50%ango_BusinessAcquisitionContingentConsiderationPayableAsPercentageOfAnnualNetSalesSecondLimit / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |
Annual net sales, second limit |  |  |  |  | 150,000,000 ango_BusinessAcquisitionContingentConsiderationPayableBasisAnnualNetSalesSecondLimitMinimum / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember | 150,000,000 ango_BusinessAcquisitionContingentConsiderationPayableBasisAnnualNetSalesSecondLimitMinimum / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |
Annual net sales |  |  |  |  | 500,000,000 ango_BusinessAcquisitionContingentConsiderationPayableBasisAnnualNetSalesSecondLimitMaximum / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember | 500,000,000 ango_BusinessAcquisitionContingentConsiderationPayableBasisAnnualNetSalesSecondLimitMaximum / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of annual net sales, third limit |  |  |  |  | 15.00%ango_BusinessAcquisitionContingentConsiderationPayableAsPercentageOfAnnualNetSalesThirdLimit / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember | 15.00%ango_BusinessAcquisitionContingentConsiderationPayableAsPercentageOfAnnualNetSalesThirdLimit / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |
Annual net sales, third limit |  |  |  |  | 500,000,000 ango_BusinessAcquisitionContingentConsiderationPayableBasisAnnualNetSalesThirdLimitMinimum / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember | 500,000,000 ango_BusinessAcquisitionContingentConsiderationPayableBasisAnnualNetSalesThirdLimitMinimum / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |
Guaranteed minimum payments payable first anniversary |  |  |  |  | 8,350,000 ango_BusinessAcquisitionContingentConsiderationPayableOnFirstAnniversary / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember | 8,350,000 ango_BusinessAcquisitionContingentConsiderationPayableOnFirstAnniversary / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |
Guaranteed minimum payments payable second anniversary |  |  |  |  | 8,000,000 ango_BusinessAcquisitionContingentConsiderationPayableOnSecondAnniversary / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember | 8,000,000 ango_BusinessAcquisitionContingentConsiderationPayableOnSecondAnniversary / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |
Guaranteed minimum payments payable third anniversary |  |  |  |  | 8,000,000 ango_BusinessAcquisitionContingentConsiderationPayableOnThirdAnniversary / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember | 8,000,000 ango_BusinessAcquisitionContingentConsiderationPayableOnThirdAnniversary / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |
Guaranteed minimum payments payable fourth anniversary |  |  |  |  | 8,000,000 ango_BusinessAcquisitionContingentConsiderationPayableOnFourthAnniversary / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember | 8,000,000 ango_BusinessAcquisitionContingentConsiderationPayableOnFourthAnniversary / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |
Guaranteed minimum payments payable fifth anniversary |  |  |  |  | 7,650,000 ango_BusinessAcquisitionContingentConsiderationPayableOnFifthAnniversary / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember | 7,650,000 ango_BusinessAcquisitionContingentConsiderationPayableOnFifthAnniversary / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of guaranteed contingent consideration | 40,000,000 ango_BusinessAcquisitionGuaranteedContingentConsiderationAtFairValue / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets acquired other than goodwill | 72,430,000 us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill / us-gaap_BusinessAcquisitionAxis = ango_VortexMedicalMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Microsulis Medical Ltd [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investment in company |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000 us-gaap_EquityMethodInvestments / us-gaap_BusinessAcquisitionAxis = ango_MicrosulisMedicalLtdMember
Ownership percentage in investment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 14.30%ango_CostMethodInvestmentOwnershipPercentage / us-gaap_BusinessAcquisitionAxis = ango_MicrosulisMedicalLtdMember
Cash payments at closing total |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,566,000 us-gaap_PaymentsToAcquireBusinessesGross / us-gaap_BusinessAcquisitionAxis = ango_MicrosulisMedicalLtdMember |  |  |  |
Business acquisition payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000 ango_BusinessAcquisitionCostOfAcquiredEntityPurchasePricePayable / us-gaap_BusinessAcquisitionAxis = ango_MicrosulisMedicalLtdMember |
Liabilities assumed |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,634,000 us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities / us-gaap_BusinessAcquisitionAxis = ango_MicrosulisMedicalLtdMember |  |  |  |
Total estimated purchase consideration |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 33,550,000 us-gaap_BusinessCombinationConsiderationTransferred1 / us-gaap_BusinessAcquisitionAxis = ango_MicrosulisMedicalLtdMember |  |  |  |
Cash payment for initial investment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000 ango_BusinessAcquisitionCostOfAcquiredEntityInitialInvestment / us-gaap_BusinessAcquisitionAxis = ango_MicrosulisMedicalLtdMember |  |  | 5,000,000 ango_BusinessAcquisitionCostOfAcquiredEntityInitialInvestment / us-gaap_BusinessAcquisitionAxis = ango_MicrosulisMedicalLtdMember |
Estimated fair value contingent consideration |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,164,000 us-gaap_BusinessCombinationContingentConsiderationLiability / us-gaap_BusinessAcquisitionAxis = ango_MicrosulisMedicalLtdMember |  |  |  |
Additional cash consideration payable period |  |  |  |  | 9 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  |  |  | 19,284,000 us-gaap_Goodwill / us-gaap_BusinessAcquisitionAxis = ango_MicrosulisMedicalLtdMember | 19,284,000 us-gaap_Goodwill / us-gaap_BusinessAcquisitionAxis = ango_MicrosulisMedicalLtdMember |  |  |  |  |  |  |  |  | 19,284,000 us-gaap_Goodwill / us-gaap_BusinessAcquisitionAxis = ango_MicrosulisMedicalLtdMember |  |  |  |
Acquisition of related cost\transaction and related costs |  |  |  |  | 257,000 us-gaap_BusinessCombinationAcquisitionRelatedCosts / us-gaap_BusinessAcquisitionAxis = ango_MicrosulisMedicalLtdMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets acquired other than goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,500,000 us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill / us-gaap_BusinessAcquisitionAxis = ango_MicrosulisMedicalLtdMember |  |  |  |
Microsulis Medical Ltd [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  | 15 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Microsulis Medical Ltd [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Devices, B.V. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total estimated purchase consideration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,700,000 us-gaap_BusinessCombinationConsiderationTransferred1 / us-gaap_BusinessAcquisitionAxis = ango_ClinicalDevicesB.V.Member |  |  |
Estimated fair value contingent consideration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000 us-gaap_BusinessCombinationContingentConsiderationLiability / us-gaap_BusinessAcquisitionAxis = ango_ClinicalDevicesB.V.Member |  |  |
Goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,800,000 us-gaap_Goodwill / us-gaap_BusinessAcquisitionAxis = ango_ClinicalDevicesB.V.Member |  |  |
Acquisition of related cost\transaction and related costs |  |  |  |  |  |  |  |  | 300,000 us-gaap_BusinessCombinationAcquisitionRelatedCosts / us-gaap_BusinessAcquisitionAxis = ango_ClinicalDevicesB.V.Member |  |  |  |  |  |  |  |  |  |
Intangible assets acquired other than goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,100,000 us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill / us-gaap_BusinessAcquisitionAxis = ango_ClinicalDevicesB.V.Member |  |  |
Stock purchase agreement payment holdback |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 400,000 ango_BusinessCombinationContingentConsiderationAssetCurrentWorkingCapitalAdjustmentHoldback / us-gaap_BusinessAcquisitionAxis = ango_ClinicalDevicesB.V.Member |  |  |
Deferred tax liability |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,200,000 us-gaap_DeferredTaxLiabilitiesDeferredExpense / us-gaap_BusinessAcquisitionAxis = ango_ClinicalDevicesB.V.Member |  |  |
Clinical Devices, B.V. [Member] | Trademark-NAMIC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired intangible asset |  |  |  |  | 3,600,000 us-gaap_IndefinitelivedIntangibleAssetsAcquired / us-gaap_BusinessAcquisitionAxis = ango_ClinicalDevicesB.V.Member / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = ango_TrademarkNamicMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Devices, B.V. [Member] | Customer relationships [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15 years |  |  |
Customer relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,400,000 us-gaap_FiniteLivedCustomerRelationshipsGross / us-gaap_BusinessAcquisitionAxis = ango_ClinicalDevicesB.V.Member / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_CustomerRelationshipsMember |  |  |
Clinical Devices, B.V. [Member] | Trademarks [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |
Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 us-gaap_FiniteLivedTrademarksGross / us-gaap_BusinessAcquisitionAxis = ango_ClinicalDevicesB.V.Member / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_TrademarksMember |  |  |
Clinical Devices, B.V. [Member] | In Process Research and Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |  |
Intangible assets acquired other than goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,600,000 us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill / us-gaap_BusinessAcquisitionAxis = ango_ClinicalDevicesB.V.Member / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_InProcessResearchAndDevelopmentMember |  |  |
Transaction Costs and Restructuring Charges [Member] | Navilyst [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business acquisition proforma net income loss attributable to different component |  |  |  |  |  |  |  |  |  |  |  |  |  | 17,600,000 us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember / us-gaap_NonrecurringAdjustmentAxis = ango_TransactionCostsAndRestructuringChargesMember |  |  |  |  |
Interest Expense [Member] | Navilyst [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business acquisition proforma net income loss attributable to different component |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,700,000 us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss / us-gaap_BusinessAcquisitionAxis = ango_NavilystMember / us-gaap_NonrecurringAdjustmentAxis = us-gaap_InterestExpenseMember |  |  |  |  |
Cash [Member] | Clinical Devices, B.V. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisitions (Additional Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash payments at closing total |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,700,000 us-gaap_PaymentsToAcquireBusinessesGross / us-gaap_BalanceSheetLocationAxis = us-gaap_CashMember / us-gaap_BusinessAcquisitionAxis = ango_ClinicalDevicesB.V.Member |  |  |

X
- Details
Name: | ango_AcquisitionsAdditionalTextualAbstract
Namespace Prefix: | ango_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business acquisition contingent consideration payable as percentage of annual net sales first limit. + References No definition available. + Details
Name: | ango_BusinessAcquisitionContingentConsiderationPayableAsPercentageOfAnnualNetSalesFirstLimit
Namespace Prefix: | ango_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business acquisition contingent consideration payable as percentage of annual net sales second limit. + References No definition available. + Details
Name: | ango_BusinessAcquisitionContingentConsiderationPayableAsPercentageOfAnnualNetSalesSecondLimit
Namespace Prefix: | ango_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business acquisition contingent consideration payable as percentage of annual net sales third limit. + References No definition available. + Details
Name: | ango_BusinessAcquisitionContingentConsiderationPayableAsPercentageOfAnnualNetSalesThirdLimit
Namespace Prefix: | ango_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business acquisition contingent consideration payable basis annual net sales first limit maximum. + References No definition available. + Details
Name: | ango_BusinessAcquisitionContingentConsiderationPayableBasisAnnualNetSalesFirstLimitMaximum
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business acquisition contingent consideration payable basis annual net sales second limit maximum. + References No definition available. + Details
Name: | ango_BusinessAcquisitionContingentConsiderationPayableBasisAnnualNetSalesSecondLimitMaximum
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business acquisition contingent consideration payable basis annual net sales second limit minimum. + References No definition available. + Details
Name: | ango_BusinessAcquisitionContingentConsiderationPayableBasisAnnualNetSalesSecondLimitMinimum
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business acquisition contingent consideration payable basis annual net sales third limit minimum. + References No definition available. + Details
Name: | ango_BusinessAcquisitionContingentConsiderationPayableBasisAnnualNetSalesThirdLimitMinimum
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business acquisition contingent consideration payable on fifth anniversary. + References No definition available. + Details
Name: | ango_BusinessAcquisitionContingentConsiderationPayableOnFifthAnniversary
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business acquisition contingent consideration payable on first anniversary. + References No definition available. + Details
Name: | ango_BusinessAcquisitionContingentConsiderationPayableOnFirstAnniversary
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business acquisition contingent consideration payable on fourth anniversary. + References No definition available. + Details
Name: | ango_BusinessAcquisitionContingentConsiderationPayableOnFourthAnniversary
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business acquisition contingent consideration payable on second anniversary. + References No definition available. + Details
Name: | ango_BusinessAcquisitionContingentConsiderationPayableOnSecondAnniversary
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business acquisition contingent consideration payable on third anniversary. + References No definition available. + Details
Name: | ango_BusinessAcquisitionContingentConsiderationPayableOnThirdAnniversary
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business acquisition contingent consideration period. + References No definition available. + Details
Name: | ango_BusinessAcquisitionContingentConsiderationPeriod
Namespace Prefix: | ango_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business acquisition cost of acquired entity initial investment. + References No definition available. + Details
Name: | ango_BusinessAcquisitionCostOfAcquiredEntityInitialInvestment
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Business acquisition cost of acquired entity purchase price payable. + References No definition available. + Details
Name: | ango_BusinessAcquisitionCostOfAcquiredEntityPurchasePricePayable
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Business acquisition guaranteed contingent consideration at fair value. + References No definition available. + Details
Name: | ango_BusinessAcquisitionGuaranteedContingentConsiderationAtFairValue
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business acquisition percentage of equity interests issued. + References No definition available. + Details
Name: | ango_BusinessAcquisitionPercentageOfEquityInterestsIssued
Namespace Prefix: | ango_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Contingent Consideration, Asset, Current, Working Capital Adjustment Holdback + References No definition available. + Details
Name: | ango_BusinessCombinationContingentConsiderationAssetCurrentWorkingCapitalAdjustmentHoldback
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Business Combination, Contingent Consideration Assumption Inputs, Sales Period + References No definition available. + Details
Name: | ango_BusinessCombinationContingentConsiderationAssumptionInputsSalesPeriod
Namespace Prefix: | ango_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cost method investment ownership percentage. + References No definition available. + Details
Name: | ango_CostMethodInvestmentOwnershipPercentage
Namespace Prefix: | ango_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Debt financing for business acquisition amount. + References No definition available. + Details
Name: | ango_DebtFinancingForBusinessAcquisitionAmount
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Proceeds from escrow fund. + References No definition available. + Details
Name: | ango_ProceedsFromEscrowFund
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Purchase consideration cash amount placed in Escrow. + References No definition available. + Details
Name: | ango_PurchaseConsiderationCashAmountPlacedInEscrow
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Purchase consideration number of common stock placed in Escrow. + References No definition available. + Details
Name: | ango_PurchaseConsiderationNumberOfCommonStockPlacedInEscrow
Namespace Prefix: | ango_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Purchase consideration placed in Escrow amount. + References No definition available. + Details
Name: | ango_PurchaseConsiderationPlacedInEscrowAmount
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Total initial amount borrowed under secured long term debt facility. + References No definition available. + Details
Name: | ango_SecuredLongTermDebtInitialBorrowingCapacity
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Transaction and Severance costs related to Acquisition. + References No definition available. + Details
Name: | ango_TransactionAndSeveranceCostsRelatedToAcquisition
Namespace Prefix: | ango_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275 + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2)-(3) -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=34752592&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of intangible assets, excluding goodwill, acquired at the acquisition date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of liabilities assumed at the acquisition date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 25 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319 + Details
Name: | us-gaap_DeferredTaxLiabilitiesDeferredExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35755396&loc=d3e33749-111570 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Gross carrying amount before accumulated amortization as of the balance sheet date to an asset acquired in a business combination representing a favorable existing relationship with customers having a finite beneficial life. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedCustomerRelationshipsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, resulting from a business combination. + References No definition available. + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gross carrying amount before accumulated amortization as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a specified period of time. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedTrademarksGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266 + Details
Name: | us-gaap_Goodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, resulting from a business combination. + References No definition available. + Details
Name: | us-gaap_IndefinitelivedIntangibleAssetsAcquired
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_CashMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ango_AvistaCapitalPartnersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ango_ClinicalDevicesB.V.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ango_MicrosulisMedicalLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ango_NavilystMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ango_VortexMedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ango_ResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ango_TechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ango_BiomedicalPolymerAdditiveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ango_PowerInjectablePortMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_NonrecurringAdjustmentAxis=ango_TransactionCostsAndRestructuringChargesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_NonrecurringAdjustmentAxis=us-gaap_InterestExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |